Breaking News

CEPI, Affinivax Partner to Advance Novel Covid-19 Vaccine

Aim to provide broad protection against SARS-CoV-2 variants, and potentially other betacoronaviruses.

Author Image

By: Charlie Sternberg

Associate Editor

CEPI, the Coalition for Epidemic Preparedness Innovations, and Affinivax Inc. have announced a partnership to advance the development of a novel vaccine that could provide broad protection against SARS-CoV-2 variants, and potentially other betacoronaviruses.   CEPI will provide funding of up to $4.5 million to support the initial development of a vaccine candidate based on Affinivax’s innovative Multiple Antigen Presenting System (MAPS) technology platform. CEPI’s investment in Affinivax will ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters